🔗 Visit the ClinicalTrials.gov page for NCT00021541
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. | Neuro Oncol | 2014 | 1.66 |
| 2 | Neurofibromatosis type 1--an update and review for the primary pediatrician. | Clin Pediatr (Phila) | 1996 | 0.91 |
| 3 | Neurofibromatosis type 1 and Ras-mediated signaling: filling in the GAPs. | Biochim Biophys Acta | 1995 | 0.86 |
| 4 | Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor. | Clin Cancer Res | 2000 | 0.79 |
| 5 | Advances in paediatric cancer treatment. | Transl Pediatr | 2014 | 0.76 |